Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • Archives
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • Editorial Team
  • Subscriptions
  • More
    • Advertising
    • Reprint Information
    • Impact Factor
    • About CJASN
    • Feedback
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • In the Loop
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • In the Loop
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • Archives
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • Editorial Team
  • Subscriptions
  • More
    • Advertising
    • Reprint Information
    • Impact Factor
    • About CJASN
    • Feedback
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
In-Depth Reviews
You have accessRestricted Access

Posttransplant Recurrence of Primary Glomerulonephritis

Claudio Ponticelli and Richard J. Glassock
CJASN December 2010, 5 (12) 2363-2372; DOI: https://doi.org/10.2215/CJN.06720810
Claudio Ponticelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Glassock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

All forms of primary GN may recur after kidney transplantation and potentially jeopardize the survival of the graft. IgA nephritis (IgAN) may recur in approximately one third of patients, more frequently in younger patients and in those with a rapid progression of the original disease. However, with the exception of few patients with rapid progression, there is no evidence that recurrence of IgAN has a deleterious effect on graft survival at least up to 10 years. Recurrence of focal segmental glomerulosclerosis (FSGS) is often associated with nephrotic proteinuria and is more frequent in children, in patients with rapid progression of the original disease, and in those who lost a previous transplant from recurrence. The natural course of recurrent FSGS is usually unfavorable. Early and intensive plasmapheresis may obtain complete or partial response in several patients. Good results have also been reported with rituximab. Idiopathic membranous nephropathy (IMN) may recur in 30% to 40% of patients. The graft survival in patients with IMN is not different than that of patients with other renal diseases. Good results with rituximab have been reported. Membranoproliferative GN (MPGN) may recur in 27% to 65% of patients. The recurrence is more frequent and the prognosis is more severe in type II MPGN. Although recurrent GN is relatively frequent and may worsen the outcome of renal allografts in some patients, its effect is diluted by several other risk-factors that may have a greater effect than recurrent GN on the long-term graft survival.

As for other patients with ESRD, renal transplantation represents the treatment of choice for patients with primary (idiopathic) GN and advanced, irreversible renal failure. However, the possibility of recurrence of the original disease after transplantation was described in a seminal paper more than 40 years ago (1), and it is now clear that all forms of GN may recur after kidney transplantation and potentially jeopardize the long-term outlook for graft survival (2,3), although the risk of recurrence is different for the various categories of primary GN. Recent studies provided new clues for better understanding the pathogenesis and thereby enhancing the possibility for improving the prevention or treatment of some forms of recurrent GN. This review will focus on the four more frequent forms of primary (idiopathic) GN that can recur after renal transplantation in Western countries; namely, IgA nephritis (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and membranoproliferative GN (MPGN). Recurrence of secondary forms of glomerular diseases will not be discussed, nor will the uncommon event of recurrent anti-neutrophil cytoplasmic antibody-positive small-vessel vasculitis in renal allografts.

IgAN

IgAN is a primary GN characterized by the dominant or co-dominant diffuse mesangial deposition of IgA, usually IgA1. The deposits consist of an aberrant galactose-deficient form of IgA1 and IgA or IgG autoantibodies to the aberrantly glycosylated IgA1 (4,5). The disease usually runs an indolent course but may lead to ESRD in 30% to 50% of patients after 25 years or more of follow-up. IgAN is one of the most common recurrent GN after transplantation (6).

A review of the literature reported that recurrences develop in approximately 33% of patients with large differences, ranging between 9% and 61%, among the different series (7). Several reasons can account for these large discrepancies. The indications for undergoing a graft biopsy were variable in the different studies and it is likely that several patients with asymptomatic hematuria and/or proteinuria never received biopsy. The follow-ups were quite different and the risk of recurrence was probably underestimated for patients followed for short times. Longer follow-up times yield higher recurrence rates. There are different racial and geographical distributions of IgAN. In some cases, IgA deposits could be already present in the donated kidneys. As an example, in a Japanese series, mesangial IgA deposits were present in 16% of 510 donated kidneys (8), although it is not clear if the deposited IgA were abnormally glycosylated.

Recurrences of IgAN can be “immunopathologic” only; discovered on a “protocol” renal biopsy in an asymptomatic patient; or “clinical,” which is delineated by abnormalities in the urine and/or renal function leading to a renal biopsy. Clinical recurrence of IgAN may occur immediately after transplantation, but on average the diagnosis is made approximately 3 years after transplantation (7,9) and is usually heralded by hematuria and low-grade proteinuria. The results of renal transplantation in patients with IgAN have been differently estimated. Some investigators (10,11) reported a more favorable outcome of the renal allograft in patients with IgAN than in other transplant recipients, but others found that graft survival in an IgAN group was similar to that of non-IgAN renal transplant recipients (12–14). An analysis of the Eurotransplant registry data reported the outcome of 1207 patients with IgAN and 7935 other renal transplant recipients. The 10-year death-censored graft survival was identical in the control group with and without the HLA-B8, DR3 haplotype (71.1% versus 70.2%) but significantly worse in IgAN patients carrying the HLA-B8, DR3 haplotype than in patients without it (52.5% versus 69.1%, P = 0.009), suggesting that this HLA haplotype may represent a risk factor for transplant recipients with IgAN (15). The limit of this study rests on the large heterogeneity between patients with IgAN and the control population. A case-control study compared the long-term outcome of 106 patients transplanted because of IgAN with that of 212 non-IgAN patients transplanted in the same period and in the same center (16). After censoring the graft failures in the first 6 months, the 10-year graft survival probability was not significantly different between the two groups: 75% in patients with IgAN and 82% in controls. The regression coefficient of the reciprocal of plasma creatinine was also similar in the two groups. In a Cox proportional hazards model analysis, IgAN recurrence was not associated with an increased risk of graft failure. Other series reported that recurrence of IgA deposition has only a modest and inconsistent effect on graft survival. In the Australia-New Zealand registry, the long-term graft survival was not affected by the increased risk of recurrence in zero-mismatched kidneys (17). In two large Asian reports, the risk of graft loss due to recurrence ranged around 3% to 4% (18,19). However, in the very long term it is possible that recurrent IgAN may represent a substantial risk factor for graft failure. Rarely, a rapidly progressive renal failure caused by an underlying crescentic GN may occur (20,21).

Recurrence tends to occur more frequently in younger patients and in those with a rapid progression of the original disease (16,22,23). It is unclear if recurrence is (24,25) or is not (16,26) more frequent in transplants using related donors. A review of the data collected by the Australia-New Zealand registry reported that biopsy-proven IgAN recurrence was significantly more frequent in zero HLA-mismatched living donor grafts (17). However, these results should be interpreted with caution because several details are lacking in retrospective reviews of registry data. Most other pretransplant characteristics are not consistently predictive for recurrence, although some authors have suggested that latent IgA deposits in the donor kidney (in “zero” time biopsies of the transplanted kidney) are highly associated with a recurrence of disease (27), and underlying crescentic GN with rapid progression to ESRD may also predict a higher risk for recurrence (28). There is now general agreement that the type and intensity of posttransplant immunosuppression does not influence the risk of IgAN recurrence. However, Berthoux et al. (29) recently reported that the 10-year cumulative recurrence rate of IgAN was 9% (3 of 29) in patients who received induction with anti-thymocyte globulins versus 41% (21 of 52) in patients who did not receive such induction therapy. The authors hypothesized that the protective effect of anti-thymocyte globulins could be related to an augmented production of regulatory T cells.

The finding that some apparently normal donors (living or deceased) may have “hidden” IgA deposits in the kidney (9) may have important relevance for pathogenesis of the recurrent disease. It may be presumed that the circulating autoantibody to exposed N-acetylgalactosamine residues on galactose-deficient IgA1 in some subjects with IgAN could react with the “planted” IgA deposits (posited also to be deficient in galactose residues thus exposing the neo-N-acetylgalactosamine epitopes) in the allograft and thus promote an immunopathological recurrence (4,6,30,31). Whether this immunopathological recurrence would rise to the level of clinical detection would depend on the activation of accessory factors (e.g., complement and cytokines [32]). Circulating immune complexes composed of IgG or IgA autoantibodies to galactose-deficient IgA1 and the relevant autoantigen might theoretically participate in recurrent disease, especially if these immune complexes escape normal reticulo-endothelial-dependent removal mechanisms (33).

No specific therapy for recurrent IgAN is currently available. A review of the U.S. Renal Data System examined the effect of immunosuppressive medication on allograft failure due to recurrent GN. After adjusting for important covariates, the use of cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, sirolimus, or prednisone was not associated with graft failure due to recurrent GN for any type of GN, including IgAN (34). Angiotensin converting enzyme inhibitors (ACEIs) may be prescribed because a study showed that their use could reduce proteinuria and blood pressure in transplant recipients with IgAN (35). However, in using these drugs one should take into account that the use of ACEIs or angiotensin receptor blockers (ARBs) in renal transplant recipients may be associated not only with reduction in proteinuria but also with significant decreases in GFR and hematocrit (36). Tonsillectomy has been suggested to be of benefit by Japanese investigators. Sixteen of 28 transplant patients with biopsy-proven recurrence of IgAN and persistent proteinuria underwent tonsillectomy alone, whereas the remaining 12 patients did not receive tonsillectomy. Proteinuria decreased significantly in all of the tonsillectomized patients but in none of the other group. The reduction in proteinuria after tonsillectomy was especially marked in patients with mild mesangial changes on renal biopsy (37). Long-term outcomes were not examined in this study. In the rare cases of recurrent IgAN associated with a rapidly progressive course and crescents at biopsy, a trial with high-dose corticosteroids, cyclophosphamide, and plasmapheresis may be attempted, although the results are usually poor.

FSGS

Idiopathic FSGS is often associated with a fully developed nephrotic syndrome (NS) and may affect children and adults. In the absence of a treatment-induced remission, FSGS commonly progresses to ESRD. Approximately 30% of patients develop recurrence of FSGS in the first kidney allograft (38). The risk of recurrence with a second graft in patients who lost a first graft because of recurrence may approach 100% (39). Two patterns of clinical presentations of recurrent FSGS after transplantation are recognized: (1) an early recurrence (the most frequent) characterized by a massive proteinuria within hours to days after implantation of the new kidney, and (2) a late recurrence that develops insidiously several months or years after transplantation.

The graft survival in patients with FSGS is lower for children than adults, particularly if the patient is white or Hispanic (40,41), and is lower in children with FSGS than in those with other renal diseases (42,43). The renal prognosis is strongly influenced by recurrence because the relative risk of graft failure is 2.25 times higher in patients with recurrent FSGS as compared with patients without recurrence (2). Graft loss caused by recurrent FSGS is significantly higher in children receiving living donor transplants compared with deceased donor transplants in children (44). Only few single-center studies reported data on graft survival in adults with FSGS. Pardon et al. (45) reported a graft survival rate of 73% at 5 years in 33 transplanted adults with FSGS, with a significant difference between the patients with (57%) or without (82%) recurrence. No comparison with a control group was made. Moroni et al. (46) compared the long-term outcomes of 52 renal transplants performed in adults with FSGS with those of 104 matched controls. At 15 years, graft survival was not significantly different: 56% in FSGS and 64% in controls. Recurrence of FSGS occurred in 12 patients (23%) and led to graft failure in 7 within 10 months (median). In the other five patients, proteinuria remitted and grafts were functioning 106 months (median) after transplantation. In the long term, patient and renal allograft survivals of adults with FSGS were comparable to those of controls.

Several clinical factors have been reported to be associated with an increased risk of recurrence, including young age, mesangial proliferation in the native kidneys, a rapid progression to ESRD, a pretransplant bilateral nephrectomy, white ethnicity, and specific aspects of genetic background (47). The histologic variant type of FSGS observed in the native kidneys does not seem to reliably predict either recurrence or type of FSGS seen on the allograft (48). There is a higher risk of recurrence in living donor transplant pediatric recipients (49); however, the reduced risk of rejection and a lower immunosuppression in living-related transplants may overcome the deleterious effect of recurrent GN. A review of the U.S. Renal Data System data reported that, after correction for other factors, living donor transplants had no association with graft loss from recurrent FSGS; rather, a living donor transplant was associated with superior overall graft survival (50). Cibrik and co-workers (51) also found that the risk of death-censored graft loss was 1% per year in adults with FSGS who received a zero HLA mismatch kidney from living donors versus a 4.4% loss per year for patients with FSGS who received a zero HLA mismatch kidney from deceased donors. Another issue concerns the living-related kidney donation to a subject affected by familial FSGS. Until recently the current opinion was that patients with familial FSGS caused by mutations of NPHS2, the gene encoding podocin, did not run any risk of recurrence after transplantation. However, there is now evidence that the risk of recurrence in patients with the NPHS2 mutation is low (but not zero) at approximately 8% (52). Therefore, caution should be observed in transplanting patients with NPHS2 mutations using the kidney of their parents who are obligate carriers of the NPHS2 mutation (53). It is also possible to speculate that in patients with genetic FSGS the transplant of a normal kidney may evoke an alloimmune response to slit diaphragm proteins.

The frequent occurrence of a rapid relapse of proteinuria after transplantation led to a postulate that a circulating factor, perhaps secreted by an abnormal clone of T cells, may induce redistribution and loss of nephrin and podocin, two critical components of the glomerular slit-diaphragm of podocytes, thereby reducing the efficiency of the glomerular barrier to proteins. However, despite intensive research by different groups of investigators (54–58), the biochemical nature of the posited circulating permeability factor(s) remains unknown, and we still lack a reliable chemical or immunoassay for its presence and quantitation.

The management of patients with recurrent FSGS and NS is difficult, controversial, and none of the multiple approaches currently available has been shown to be consistently beneficial. Perhaps more targeted approaches will emerge based on our improving knowledge of podocyte biology and function. An amelioration of proteinuria has been reported in children treated with intravenous cyclosporine at high doses (59–62). This anti-proteinuric effect of cyclosporine may be attributed to suppression of T cells and inhibited production of their cytokines and to the inhibition of calcineurin-mediated dephosphorylation of synaptopodin, a protein critical for stabilizing the actin cytoskeleton in kidney podocytes (63). Cyclosporine and other calcineurin inhibitors thus have systemic immunoregulatory and local podocyte modulatory actions: Either one or both can be responsible for their anti-proteinuric effects in recurrent FSGS. However, the long-term efficacy and tolerance of such a therapy remains to be established. The most commonly used therapeutic approach is the use of plasma exchange (PE) or immunoadsorption with protein A (59,64–66). A review of the literature reported that 70% of children and 63% of adults with recurrent FSGS who received PE entered complete or partial remission of proteinuria (47). However, all studies were retrospective, uncontrolled, and most of them had only short-term follow-ups. In a pilot trial, 10 adults with FSGS recurrence received concomitantly high-dose steroids, intravenous cyclosporine for 14 days followed by oral cyclosporine therapy, and an intensive and prolonged course of PE. Complete, rapid, and sustained remission was obtained in 9 of 10 patients. At month 3 and month 12, proteinuria was 0.16 and 0.19 g/d, respectively. PE was stopped at month 9 in all patients except for one patient who remained PE dependent (64). A protective role of prophylactic PE before transplantation has also been reported (65,66). Several single-case reports pointed out the benefit of rituximab when given alone or in combination with PE (67–72), but failures were also reported (73–76). Currently, PE combined with high-dose calcineurin inhibitors with or without rituximab seems to be the most promising approach, but further controlled trials are needed to define the optimal therapeutic regimens to treat recurrence of FSGS (77).

Despite the risk of recurrence, patients with FSGS should not be excluded from transplantation. In the case of living donation, the possibility of recurrence and its consequences should be clearly explained to the donor and the recipient and preemptive PE should be planned in advance of transplantation. An early and aggressive treatment should be provided if proteinuria develops.

IMN

IMN is characterized histologically by uniform thickening of the glomerular capillary due to immune-complex deposits in the outer or subepithelial aspect of the glomerular basement membrane. IMN is a frequent cause of NS in adults and may lead in 40% to 50% of patients to ESRD in the long term (78,79). A recurrence of IMN after renal transplantation is probably more frequent than generally estimated. Up to now, almost 300 cases of recurrent MN have been reported in renal transplant patients (80–108), most cases occurring in adults. However, the true proportion of recurrence is difficult to assess because the indications for graft biopsy are extremely variable among transplant centers. Moreover a de novo form of secondary MN may develop in transplanted kidneys showing a histologic pattern indistinguishable from recurrent IMN. This de novo MN may occur even more frequently than the recurrent MN. In a study with protocol biopsies, 6 of 17 cases of MN were identified; of them 6 (35%) were considered to be recurrent IMN and 11 (65%) de novo MN (108). With these difficulties in mind, the rate of IMN recurrence has been estimated to range between 30% and 44% (96,108).

Recurrence of IMN is usually diagnosed between the 2nd and 3rd year after transplantation, but earlier and later cases have been described. So far, no clinical or histologic factor seems to reliably predict the risk of recurrence. In one series (89) posttransplant recurrence occurred earlier in recipients of a living-donor allograft (mean 9.3 months after transplantation) than in deceased donor transplant recipients (18.2 months). However, a study from Hong Kong reported that MN (including recurrent IMN and de novo MN) occurred later, at a mean of 45 months after transplantation (98). The initial clinical manifestations of recurrent IMN may be mild or absent, and in several patients recurrence could be detected only by protocol renal biopsies (101). However, many patients show a progressive increase in proteinuria over time and can eventually develop a full-blown NS. Proteinuria may spontaneously improve or even disappear only rarely (94,102).

The results of renal transplantation in patients with IMN are not different than those observed in patients with other renal diseases, including primary GN. The Australian registry reported that the actuarial renal allograft survival at 10 years was similar in patients transplanted because of IMN and in 1505 transplanted patients with other renal diseases (3). The outcome of recurrent IMN may be as variable as in the original native disease and its effect on graft survival has been differently estimated. Some studies have reported that 60% to 65% of patients with recurrent IMN progressed to ESRD in a mean of 4 years after diagnosis (89,95). However, in many patients the graft failure was caused by rejection rather than recurrence of IMN. Other investigators reported that there was not any significant difference in death, graft failures, or serum creatinine between IMN with recurrent disease and those without recurrence after mean follow-ups of 73 and 57 months, respectively (108).

The mechanisms leading to IMN recurrence are still far from being elucidated. There is now evidence that MN is triggered by autoantibodies directed against podocyte proteins. Debiec et al. (109) identified in newborns from mothers deficient in these podocyte proteins circulating specific antibodies (IgG4 and IgG1) against neutral endopeptidase. This is an example of an allo-immune reaction causing MN and may be more akin to the pathogenesis of de novo MN. Recently, circulating autoantibodies directed against other podocyte enzymes, such as M-type phospholipase-2 receptors (110) and aldose reductase and manganese superoxide dismutase (111), have been detected in adults with IMN and are uniformly absent in secondary forms of MN. The expression of these autoantigens in podocytes can trigger the production of specific antibodies (mainly IgG4 and IgG1) and in situ deposits of immune complexes on the epithelial side of the glomerular basement membrane, with consequent activation of complement, oxygen radicals, and other components of the inflammatory response. As far as the pathogenesis of recurrent IMN is concerned, it is possible to hypothesize that recurrent disease is due to the reaction of autoantibodies (anti-phospholipase A2 receptor) from the circulation with conformational epitopes exposed or genetically determined in the donor kidney. This possibility has been recently confirmed by clinical observations (112).

Symptomatic treatment with diuretics, ACEIs, ARBs, hypolipemic drugs, and anticoagulants may help in reducing the signs and symptoms related to the NS in recurrent IMN. No convincing evidence exists that corticosteroids, cytotoxic drugs, or other immunosuppressive agents are of benefit in recurrent IMN. Rituximab has shown very promising effects in patients with IMN in native kidneys (113,114) and has also been used successfully in anecdotal cases of posttransplant IMN recurrence (100,103,104). In a recent study, eight patients with recurrent IMN and a mean proteinuria of 4.5 g/d were given two separate doses of intravenous rituximab (1000 mg each) 2 weeks apart. Twelve months later, 35% of patients had a complete remission and another 40% had a partial remission. After 24 months, one patient had relapsed. Post-treatment biopsies showed reabsorption of electron-dense immune deposits in six of seven patients (107). In another series, four patients with recurrent IMN and severe proteinuria were given rituximab, either at a weekly dose of 375 mg/m2 for 4 weeks, or at a dose of 100 mg repeated 2 weeks later. Two patients responded to the first course and the other two patients received a second course of rituximab. Mean proteinuria decreased from 4.0 to 1.8 g per day, and serum creatinine remained stable at approximately 1.5 mg/dl (108).

MPGN Types I and II (Dense Deposit Disease)

MPGN is “pattern of injury” rather than a disease (115). It is now known to have a very diverse array of underlying causes, and the group designated as ‘idiopathic” MPGN has correspondingly declined in size (115). Nevertheless. MPGN is common cause of recurrent GN in allografts. The reported rate of recurrence of MPGN has been quite variable (27% to 65%) (116). MPGN has previously been divided into subtypes (types I, II, III, etc.) on the basis of ultrastructural features. Type I MPGN characteristically has subendothelial electron-dense deposits containing IgG and C3, which presumably represent immune complexes. Type II MPGN (also known as dense deposit disease [DDD]) shows an electron-dense transformation of the glomerular basement membrane and deposition of C3 (and other complement components without IgG deposition). In previous series, types I and II MPGN (DDD) were considered together, whereas the current trend is to separate DDD as a unique clinicopathologic entity having a higher risk of recurrence than typical type I MPGN (117). Differences in recurrence rates between type I MPGN and DDD may relate more to the superimposition of crescents than to the underlying ultrastructural features (118). Risk of recurrence may be marginally higher in living related donors. The most important aspect of recurrent MPGN or DDD is the identification of the processes responsible for the original native disease. Recurrent MPGN due to lupus nephritis, monoclonal gammopathies, thrombotic microangiopathies, and more frequently HCV infection (119) do occur, but they are beyond the scope of this review.

Recurrent MPGN type I can have significant deleterious effects on graft survival, especially when superimposed extensive crescentic disease is present (118), and thus should be prevented in so far as is possible by careful pretransplant evaluation.

Intensification of immunosuppressive therapy in recurrent MPGN can be hazardous because it may lead to overimmunosuppression and has little documented effect on the outcome of the recurrence, except perhaps when extensive crescentic disease is present. Occasional anecdotes and small series have suggested that improvement may be seen in recurrent MPGN type I with cyclophosphamide (120) or high-dose mycophenolate mofetil (121), but no controlled trial has yet confirmed the efficacy or safety of these approaches. Treatment of truly “idiopathic” recurrent MPGN is generally very disappointing and graft loss due to recurrence is common (116).

DDD

This disease has a very high risk of recurrence (approaching 100%). Most patients have low serum C3 levels, and 70% to 80% also have a circulating autoantibody to C3Bb known as C3 nephritic factor (C3Nef). Some patients with DDD may also have an abnormality in complement cascade regulation such as deficiencies of factor H) (122). Thus, hypocomplementemia and/or isolated C3 deposits suggesting DDD in a native kidney biopsy showing a pattern of MPGN is a feature highly associated with risk for recurrence (115,116), When ultrastructural analysis of the native kidney biopsy reveals DDD an evaluation for complement dysregulation (factor H, I, or membrane cofactor protein levels) seems appropriate. Serum C3 nephritic factor levels do not reliably predict the risk of recurrence of DDD in the renal allograft. Subtle monoclonal Ig deposition diseases such as light-chain deposition disease can also mimic idiopathic MPGN and contribute to recurrent disease (115,116), frequently appearing within a few months after transplantation (116). Finally, a newly described entity, known as “GN C3,” may also have clinical features similar to DDD and type I MPGN, but it lacks the ultrastructural features of typical DDD and fails to show any immune complex deposits characteristically found in type I MPGN. Only C3 without IgG deposits are observed. Deficiencies of complement factor H, I, or membrane cofactor protein are frequently noted. The risk of recurrence of GN C3 in the allograft is not well known but would be presumed to be elevated if abnormalities in complement dysregulation are found.

The successful treatment of an established recurrence of DDD is problematical, so prevention and anticipatory management based on precise assessment of the underlying mechanism responsible for the MPGN is very important. Patients with complement dysregulation (e.g., factor H deficiency) should receive replacement infusions (fresh frozen plasma) before and after grafting (123), although no controlled trials of the efficacy of this approach have yet been conducted. Plasma therapy has shown very promising results in atypical hemolytic uremic syndrome associated with genetic mutations in factor H (124,125). PE (with fresh frozen plasma replacement) and/or rituximab might also be helpful in patients with a neutralizing autoantibody to factor H. Eculizumab (a monoclonal antibody to C5a) may also be beneficial, but this has not been yet been shown in a randomized trial (123). Patients with genetic causes for factor H or I deficiency may require combined liver and kidney transplantation to avoid recurrences (125), but this is mainly derived from experience with hereditary forms of atypical hemolytic uremic syndrome also associated with factor H deficiency (126). Patients with documented underlying monoclonal gammopathies should receive appropriate aggressive chemotherapy and/or autologous stem cell transplantation before kidney grafting so as to minimize the risk of recurrence.

Conclusions

Although recurrent GN is relatively frequent and may worsen the outcome of renal allograft in some patients, its effect on the fate of a renal allograft is diluted by several other risk factors, including death with functioning graft, the quality of the donated kidney, rejection, drug nephrotoxicity, infections, and other renal and extrarenal complications such as hypertension, diabetes, coronary artery disease, liver disease, and cancer. These factors may have a greater effect than recurrent GN on long-term graft survival, as demonstrated by large series showing that overall long-term graft survival is similar in recipients with many forms of primary GN and in those with other renal diseases (2,127).

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2010 by the American Society of Nephrology

References

  1. ↵
    1. Glassock RJ,
    2. Feldman D,
    3. Reynolds ES,
    4. Dammin GJ,
    5. Merrill JP
    : Human renal isografts: A clinical and pathologic analysis. Medicine (Baltimore) 47: 411–454, 1968
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hariharan S,
    2. Adams MB,
    3. Brennan DC,
    4. Davis CL,
    5. First RM,
    6. Johnson CP,
    7. Ouseph R,
    8. Peddi VR,
    9. Pelz CJ,
    10. Roza AM,
    11. Vincenti F
    : Recurrent and de novo glomerular disease after renal transplantation. A report from the Renal Allograft Disease Registry (RADR). Transplantation 68: 635–641, 1999
    OpenUrlCrossRefPubMed
  3. ↵
    1. Briganti EM,
    2. Russ GR,
    3. McNeil JJ,
    4. Atkins RC,
    5. Chadbans J
    : Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347: 103–109, 2002
    OpenUrlCrossRefPubMed
  4. ↵
    1. Novak J,
    2. Julian B,
    3. Tomana M,
    4. Mestecky J
    : IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28: 78–87, 2008
    OpenUrlCrossRefPubMed
  5. ↵
    1. Barratt J,
    2. Eitner F,
    3. Feehally J,
    4. Floege J
    : Immune complex formation in IgA nephropathy: A case of the “right” antibodies in the “wrong” place at the “wrong” time? Nephrol Dial Transplant 24: 3620–3623, 2009
    OpenUrlFREE Full Text
  6. ↵
    1. Furness PN,
    2. Roberts ISD,
    3. Briggs JD
    : Recurrent glomerular disease in transplants. Transplant Proc 34: 242, 2002
    OpenUrl
  7. ↵
    1. Ponticelli C,
    2. Traversi L,
    3. Banfi G
    : Renal transplantation in patients with IgA mesangial glomerulonephritis. Pediatr Transplant 8: 334–338, 2004
    OpenUrlCrossRefPubMed
  8. ↵
    1. Suzuki K,
    2. Honda K,
    3. Tanabe K,
    4. Toma H,
    5. Nihei H,
    6. Yamaguchi Y
    : Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63: 2286–2294, 2003
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hariharan S,
    2. Savin VJ
    : Recurrent and de novo disease after renal transplantation: A report from the Renal Allograft Disease Registry. Pediatr Transplant 8: 349–350, 2004
    OpenUrlCrossRefPubMed
  10. ↵
    1. Lim EC,
    2. Chia D,
    3. Terasaki PI
    : Studies of sera from IgA nephropathy patients to explain high kidney graft survival. Hum Immunol 32: 81–86, 1991
    OpenUrl
  11. ↵
    1. Jeong HJ,
    2. Park SK,
    3. Cho YM,
    4. Kim MS,
    5. Kim YS,
    6. Choi J,
    7. Kim SI,
    8. Lim BJ
    : Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy. Hum Pathol 39: 1511–1518, 2008
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bumgardner GL,
    2. Amend WC,
    3. Ascher NL,
    4. Vincenti FG
    : Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 65: 1053–1060, 1998
    OpenUrlCrossRefPubMed
  13. ↵
    1. Soler MJ,
    2. Mir M,
    3. Rodriguez E,
    4. Orfila A,
    5. Munne A,
    6. Vázquez S,
    7. Lloveras J,
    8. Puig JM
    : Recurrence of IgA nephropathy and Henoch–Schoenlein purpura after kidney transplantation: Risk factors and graft survival. Transplant Proc 37: 3705–3709, 2005
    OpenUrlCrossRefPubMed
  14. ↵
    1. Chacko B,
    2. George JT,
    3. Neelakantan N,
    4. Korula A,
    5. Chakko JK
    : Outcomes of renal transplantation in patients with immunoglobulin A nephropathy in India. J Postgrad Med 53: 92–95, 2007
    OpenUrlCrossRefPubMed
  15. ↵
    1. Andresdottir MB,
    2. Haasnoot GW,
    3. Persijn GG,
    4. Claas FH
    : HLA-B8, DR3: A new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy. Clin Transplant 23: 660–665, 2009
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ponticelli C,
    2. Traversi L,
    3. Feliciani A,
    4. Cesana BM,
    5. Banfi G,
    6. Tarantino A
    : Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 60: 1948–1954, 2001
    OpenUrlCrossRefPubMed
  17. ↵
    1. McDonald SP,
    2. Russ GR
    : Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 27, 759–762, 2006
    OpenUrl
  18. ↵
    1. Choy BY,
    2. Chan TM,
    3. Lo SK,
    4. Lo WK,
    5. Lai KN
    : Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 18: 2399–2404, 2003
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Ng YS,
    2. Vathsala A,
    3. Chew ST,
    4. Chiang GS,
    5. Woo KT
    : Long-term outcome of renal allografts in patients with immunoglobulin A nephropathy. Med J Malaysia 62: 109–113, 2007
    OpenUrlPubMed
  20. ↵
    1. Benabdallah L,
    2. Rerolle JP,
    3. Peraldi MN,
    4. Noël LH,
    5. Bruneel MF,
    6. Carron PL,
    7. Morelon E,
    8. Kreis H
    : An unusual recurrence of crescentic nephritis after renal transplantation for IgA nephropathy. Am J Kidney Dis 40: E20, 2002
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kowalewska J,
    2. Yuan S,
    3. Sustento-Reodica N,
    4. Nicosia RF,
    5. Smith KD,
    6. Davis CL,
    7. Alpers CE
    : IgA nephropathy with crescents in kidney transplant recipients. Am J Kidney Dis 45: 167–175, 2005
    OpenUrlCrossRefPubMed
  22. ↵
    1. Chailimpamontree W,
    2. Dmitrienko S,
    3. Li G,
    4. Balshaw R,
    5. Magil A,
    6. Shapiro RJ,
    7. Landsberg D,
    8. Gill J,
    9. Keown PA
    ; Genome Canada Biomarkers in Transplantation Groupe: Probability, predictors, and prognosis of posttransplantation glomerulonephritis. J Am Soc Nephrol 20: 843–851, 2009
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Floege J
    : Recurrent IgA nephropathy after renal transplantation. Semin Nephrol 24: 287–291, 2004
    OpenUrlCrossRefPubMed
  24. ↵
    1. Andresdottir MB,
    2. Haasnot GW,
    3. Doxiadis II,
    4. Persjin GG,
    5. Claas FH
    : Exclusive characteristics of graft survival and risk factors in recipients of immunoglobulin A nephropathy: A retrospective analysis of registry data. Transplantation 80: 1012–1018, 2005
    OpenUrlCrossRefPubMed
  25. ↵
    1. Wang AYM,
    2. Lai FM,
    3. Yu AWY,
    4. Lam PK,
    5. Chow KM,
    6. Choi PC,
    7. Lui SF,
    8. Li PK
    : Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 38: 588–596, 2001
    OpenUrlCrossRefPubMed
  26. ↵
    1. Kim YS,
    2. Moon JI,
    3. Jeong HJ,
    4. Kim MS,
    5. Kim SI,
    6. Choi KH,
    7. Lee HY,
    8. Han DS,
    9. Park K
    : Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 71: 233–238, 2001
    OpenUrlCrossRefPubMed
  27. ↵
    1. Moriyama T,
    2. Nitta K,
    3. Suzuki K,
    4. Honda K,
    5. Horita S,
    6. Uchida K,
    7. Yumura W,
    8. Tanabe K,
    9. Toma H,
    10. Nihei H,
    11. Yamaguchi Y
    : Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant 19[Suppl 14]: 41–48, 2005
    OpenUrlCrossRefPubMed
  28. ↵
    1. Tang Z,
    2. Ji SM,
    3. Chen DR,
    4. Wen JQ,
    5. Liu ZH,
    6. Li LS
    : Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation. Ren Fail 30: 611–616, 2008
    OpenUrlCrossRefPubMed
  29. ↵
    1. Berthoux F,
    2. El Deeb S,
    3. Mariat C,
    4. Diconne E,
    5. Laurent B,
    6. Thibaudin L
    : Anti-thymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 85: 1505–1507, 2008
    OpenUrlCrossRefPubMed
  30. ↵
    1. Suzuki H,
    2. Fan R,
    3. Zhang Z,
    4. Brown R,
    5. Hall S,
    6. Julian BA,
    7. Chatham WW,
    8. Suzuki Y,
    9. Wyatt RJ,
    10. Moldoveanu Z,
    11. Lee JY,
    12. Robinson J,
    13. Tomana M,
    14. Tomino Y,
    15. Mestecky J,
    16. Novak J
    : Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1666–1677, 2009
    OpenUrl
  31. ↵
    1. Glassock RJ
    : Analyzing antibody activity in IgA nephropathy. J Clin Invest 119: 1450–1452, 2009
    OpenUrlPubMed
  32. ↵
    1. Coppo R,
    2. Feehally J,
    3. Glassock RJ
    : IgA nephropathy at two score and one. Kidney Int 77: 181–186, 2010
    OpenUrlCrossRefPubMed
  33. ↵
    1. Mestecky J,
    2. Suzuki H,
    3. Yanagihara T,
    4. Moldoveneanu Z,
    5. Tomana M,
    6. Matousovic C,
    7. Julian BA,
    8. Novak J
    : IgA nephropathy: Current views of immune complex formation. Contrib Nephrol 157: 58–63, 2007
    OpenUrl
  34. ↵
    1. Mulay AV,
    2. van Walraven C,
    3. Knoll GA
    : Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 9: 804–811, 2009
    OpenUrlCrossRefPubMed
  35. ↵
    1. Oka K,
    2. Imai E,
    3. Moriyama T,
    4. Akagi Y,
    5. Ando A,
    6. Hori M,
    7. Okuyama A,
    8. Toki K,
    9. Kyo M,
    10. Kokado Y,
    11. Takahara S
    : A clinicopathological study of IgA nephropathy in renal transplant recipients: Beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 15: 689–695, 2000
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Hiremath S,
    2. Fergusson D,
    3. Doucette S,
    4. Mulay AV,
    5. Knoll GA
    : Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 7: 2350–2360, 2007
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kennoki T,
    2. Ishida H,
    3. Yamaguchi Y,
    4. Tanabe K
    : Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation 88: 935–941, 2009
    OpenUrlCrossRefPubMed
  38. ↵
    1. Couser W
    : Recurrent glomerulonephritis in the renal allograft: An update of selected areas. Exp Clin Transplant 3: 283–288, 2005
    OpenUrlPubMed
  39. ↵
    1. Newstead CG
    : Recurrent disease in renal transplants. Nephrol Dial Transplant 18[Suppl 6]: 68–74, 2003
    OpenUrlCrossRef
  40. ↵
    1. Tejani A,
    2. Stablein DH
    : Recurrence of focal segmental glomerulosclerosis posttransplantation: A special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 2[Suppl]: S258–S263, 1992
    OpenUrlAbstract
  41. ↵
    1. Fine RN
    : Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 22: 496–502, 2007
    OpenUrlCrossRefPubMed
  42. ↵
    1. Carraro M,
    2. Caridi G,
    3. Bruschi M,
    4. Artero M,
    5. Bertelli R,
    6. Zennaro C,
    7. Musante L,
    8. Candiano G,
    9. Perfumo F,
    10. Ghiggeri GM
    : Serum glomerular permeability activity in patients with podocin mutation (NPHS2) and steroid resistant nephrotic syndrome. J Am Soc Nephrol 13: 1946–1952, 2002
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Fuentes GM,
    2. Meseguer CG,
    3. Carrion AP,
    4. Hijosa MM,
    5. Garcia-Pose A,
    6. Melgar AA,
    7. Torres MN
    : Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 25: 529–534, 2010
    OpenUrlCrossRefPubMed
  44. ↵
    1. Baum MA
    : Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 8: 329–333, 2004
    OpenUrlCrossRefPubMed
  45. ↵
    1. Pardon A,
    2. Audard V,
    3. Caillard S,
    4. Moulin B,
    5. Desvaux D,
    6. Bentaarit B,
    7. Remy P,
    8. Sahali D,
    9. Roudot-Thoraval F,
    10. Lang P,
    11. Grimbert P
    : Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 21: 1053–1059, 2006
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Moroni G,
    2. Gallelli B,
    3. Quaglini S,
    4. Banfi G,
    5. Montagnino G,
    6. Messa P
    : Long-term outcome of renal transplantation in adults with focal segmental glomerulosclerosis. Transpl Int 23: 208–216, 2010
    OpenUrlCrossRefPubMed
  47. ↵
    1. Ponticelli C
    : Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 25: 25–31, 2010
    OpenUrlFREE Full Text
  48. ↵
    1. Canaud G,
    2. Dion D,
    3. Zuber J,
    4. Gubler MC,
    5. Sberro R,
    6. Thervet E,
    7. Snanoudj R,
    8. Charbit M,
    9. Salomon R,
    10. Martinez F,
    11. Legendre C,
    12. Noel LH,
    13. Niaudet P
    : Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: Course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 25: 1321–1328, 2010
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Baum MA,
    2. Stablein DM,
    3. Panzarino VM,
    4. Tejani A,
    5. Harmon WE,
    6. Alexander SR
    : Loss of living donor renal allograft advantage in children with focal segmental glomerulosclerosis. Kidney Int 59: 328–333, 2001
    OpenUrlCrossRefPubMed
  50. ↵
    1. Abbott KC,
    2. Sawyers ES,
    3. Oliver JD III.,
    4. Ko CW,
    5. Kirk AD,
    6. Welch PG,
    7. Peters TG,
    8. Agodoa LY
    : Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 237: 366–373, 2001
    OpenUrl
  51. ↵
    1. Cibrik DM,
    2. Kaplan B,
    3. Campbell DA,
    4. Meier-Kriesche HU
    : Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 3: 64–67, 2003
    OpenUrlPubMed
  52. ↵
    1. Weber S,
    2. Gribouval O,
    3. Esquivel EL,
    4. Morinière V,
    5. Tête MJ,
    6. Legendre C,
    7. Niaudet P,
    8. Antignac C
    : NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66: 571–579, 2004
    OpenUrlCrossRefPubMed
  53. ↵
    1. Vincenti F,
    2. Ghiggeri GM
    : New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 5: 1179–1185, 2005
    OpenUrlCrossRefPubMed
  54. ↵
    1. Savin VJ,
    2. Sharma R,
    3. Sharma M,
    4. McCarthy ET,
    5. Swan SK,
    6. Ellis E,
    7. Lovell H,
    8. Warady B,
    9. Gunwar S,
    10. Chonko AM,
    11. Artero M,
    12. Vincenti F
    : Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334: 878–883, 1996
    OpenUrlCrossRefPubMed
  55. ↵
    1. Dantal J,
    2. Godfrin Y,
    3. Koll R,
    4. Perretto S,
    5. Naulet J,
    6. Bouhours JF,
    7. Soulillou JP
    : Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9: 1709–1715, 1998
    OpenUrlAbstract
  56. ↵
    1. Rea R,
    2. Smith C,
    3. Sandhu K,
    4. Kwan J,
    5. Tomson C
    : Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 416–417, 2001
    OpenUrlFREE Full Text
  57. ↵
    1. Savin VJ,
    2. McCarthy ET,
    3. Sharma M
    : Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 23: 147–160, 2003
    OpenUrlCrossRefPubMed
  58. ↵
    1. Trachtman H,
    2. Greenbaum LA,
    3. McCarthy ET,
    4. Sharma M,
    5. Gauthier BG,
    6. Frank R,
    7. Warady B,
    8. Savin VJ
    : Glomerular permeability activity: Prevalence and prognostic value in pediatric patients with idiopathic nephrotic syndrome. Am J Kidney Dis 44: 604–610, 2004
    OpenUrlCrossRefPubMed
  59. ↵
    1. Canaud G,
    2. Martinez F,
    3. Noel LH,
    4. Mamzer MF,
    5. Niaudet P,
    6. Legendre C
    : Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando) 24: 121–128, 2010
    OpenUrlCrossRefPubMed
  60. ↵
    1. Ingulli E,
    2. Tejani A
    : Incidence, treatment and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children: A single center experience. Transplantation 51: 401–405, 1991
    OpenUrlPubMed
  61. ↵
    1. Salomon R,
    2. Gagnadoux MF,
    3. Niaudet P
    : Intravenous cyclosporine therapy in recurrent nephrotic syndrome after transplantation in children. Transplantation 75: 810–814, 2003
    OpenUrlCrossRefPubMed
  62. ↵
    1. Raafat RH,
    2. Kalia A,
    3. Travis LB,
    4. Diven SC
    : High-dose cyclosporine therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 44: 50–56, 2004
    OpenUrlCrossRefPubMed
  63. ↵
    1. Faul C,
    2. Donnelly M,
    3. Merscher-Gomez S,
    4. Chang YH,
    5. Franz S,
    6. Delfgaauw J,
    7. Chang JM,
    8. Choi HY,
    9. Campbell KN,
    10. Kim K,
    11. Reiser J,
    12. Mundel P
    : The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931–938, 2008
    OpenUrlCrossRefPubMed
  64. ↵
    1. Canaud G,
    2. Zuber J,
    3. Sberro R,
    4. Royale V,
    5. Anglicheau D,
    6. Snanoudj R,
    7. Gaha K,
    8. Thervet E,
    9. Lefrère F,
    10. Cavazzana-Calvo M,
    11. Noël LH,
    12. Méjean A,
    13. Legendre C,
    14. Martinez F
    : Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: A pilot study. Am J Transplant 9: 1081–1086, 2009
    OpenUrlCrossRefPubMed
  65. ↵
    1. Ohta T,
    2. Kawaguchi H,
    3. Hattori M,
    4. Komatsu Y,
    5. Akioka Y,
    6. Nagata M,
    7. Shiraga H,
    8. Ito K,
    9. Takahashi K,
    10. Ishikawa N,
    11. Tanabe K,
    12. Yamaguchi Y,
    13. Ota K
    : Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 71:628–633, 2001
    OpenUrlCrossRefPubMed
  66. ↵
    1. Gohh RY,
    2. Yango AF,
    3. Morrissey PE,
    4. Monaco AP,
    5. Gautam A,
    6. Sharma M,
    7. McCarthy ET,
    8. Savin VJ
    : Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5: 2907–2912, 2005
    OpenUrlCrossRefPubMed
  67. ↵
    1. Apeland T,
    2. Hartmann A
    : Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 23: 2091–2094, 2008
    OpenUrlFREE Full Text
  68. ↵
    1. Meyer TN,
    2. Thaiss F,
    3. Stahl RA
    : Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 20:1066–1071, 2008
    OpenUrlCrossRef
  69. ↵
    1. Westphal S,
    2. Hansson S,
    3. Mjörnstedt L,
    4. Mölne J,
    5. Swerkersson S,
    6. Friman S
    : Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab. Transplant Proc 38: 2659–2660, 2006
    OpenUrlCrossRefPubMed
  70. ↵
    1. Hristea D,
    2. Hadaya K,
    3. Marangon N,
    4. Buhler L,
    5. Villard J,
    6. Morel P,
    7. Martin PY
    : Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20: 102–105, 2007
    OpenUrlCrossRefPubMed
  71. ↵
    1. Dello Strologo L,
    2. Guzzo I,
    3. Laurenzi C,
    4. Vivarelli M,
    5. Parodi A,
    6. Barbano G,
    7. Camilla R,
    8. Scozzola F,
    9. Amore A,
    10. Ginevri F,
    11. Murer L
    : Use of Rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88: 417–420, 2009
    OpenUrlCrossRefPubMed
  72. ↵
    1. Sakai K,
    2. Takasu J,
    3. Nihei H,
    4. Yonekura T,
    5. Aoki Y,
    6. Kawamura T,
    7. Mizuiri S,
    8. Aikawa A
    : Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 24[Suppl 22]: 60–65, 2010
    OpenUrlCrossRefPubMed
  73. ↵
    1. Kamar N,
    2. Faguer S,
    3. Esposito L,
    4. Guitard J,
    5. Nogier MB,
    6. Durand D,
    7. Rostaing L
    : Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 67: 250–254, 2007
    OpenUrlPubMed
  74. ↵
    1. El-Firjani A,
    2. Hoar S,
    3. Karpinski J,
    4. Bell R,
    5. Deschenes MJ,
    6. Knoll GA
    : Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 23: 425, 2008
    OpenUrlFREE Full Text
  75. ↵
    1. Yabu JM,
    2. Ho B,
    3. Scandling JD,
    4. Vincenti F
    : Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 8: 222–227, 2008
    OpenUrlPubMed
  76. ↵
    1. Rodríguez-Ferrero M,
    2. Ampuero J,
    3. Anaya F
    : Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 41: 2406–2408, 2009
    OpenUrlCrossRefPubMed
  77. ↵
    1. Vinai M,
    2. Waber P,
    3. Seikaly MG
    : Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth review. Pediatr Transplant 14: 314–325, 2010
    OpenUrlCrossRefPubMed
  78. ↵
    1. Hogan SL,
    2. Muller KE,
    3. Jennette JC,
    4. Falk RJ
    : A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25: 862–875, 1995
    OpenUrlPubMed
  79. ↵
    1. Ponticelli C,
    2. Passerini P
    : Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy? J Nephrol 23: 156–163, 2010
    OpenUrlPubMed
  80. ↵
    1. Crosson JT,
    2. Wathen RL,
    3. Raij L,
    4. Andersen RC,
    5. Andersen WR
    : Recurrence of membranous nephropathy after renal transplantation. Arch Int Med 135: 1101–1106, 1975
    OpenUrlCrossRefPubMed
  81. ↵
    1. Petersen VP,
    2. Olsen TS,
    3. Kissmeyer-Nielsen F,
    4. Bohman SO,
    5. Hansen ES,
    6. Skov PE,
    7. Solling K
    : Late failure of human renal transplant. An analysis of transplant disease and graft failure among 125 recipients surviving for one to eight years. Medicine 54: 45–69, 1975
    OpenUrlCrossRefPubMed
  82. ↵
    1. Morzycka M,
    2. Croker BP,
    3. Seigler HF,
    4. Tisher CC
    : Evaluation of recurrent glomerulonephritis in kidney allografts. Am J Med 72: 588–598, 1982
    OpenUrlCrossRefPubMed
  83. ↵
    1. Berger BE,
    2. Vincenti F,
    3. Biava C,
    4. Amend WJ Jr.,
    5. Feduska N,
    6. Salvatierra O Jr.
    : De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation 35: 315–319, 1983
    OpenUrlCrossRefPubMed
  84. ↵
    1. Obermiller LE,
    2. Hoy WE,
    3. Eversole M,
    4. Sterling WA
    : Recurrent membranous glomerulonephritis in two renal transplants. Transplantation 40: 100–102, 1985
    OpenUrlCrossRefPubMed
  85. ↵
    1. Bansal VK,
    2. Kozeny GA,
    3. Fresco R,
    4. Vertuno LL,
    5. Hano JE
    : De novo membranous nephropathy following renal transplantation between conjoint twins. Transplantation 41: 404–406, 1986
    OpenUrlCrossRefPubMed
  86. ↵
    1. Montagnino G,
    2. Colturi C,
    3. Banfi G,
    4. Aroldi A,
    5. Tarantino A,
    6. Ponticelli C
    : Membranous nephropathy in cyclosporine-treated renal transplant recipients. Transplantation 47: 725–727, 1989.
    OpenUrlPubMed
  87. ↵
    1. Truong L,
    2. Gelfand J,
    3. D'Agati V,
    4. Tomaszewski J,
    5. Appel G,
    6. Hardy M,
    7. Pirani CL
    : De novo membranous nephropathy in renal allograft. A report of ten cases and review of the literature. Am J Kidney Dis 14: 131–141, 1989
    OpenUrlPubMed
  88. ↵
    1. Monga G,
    2. Mazzucco G,
    3. Basolo B,
    4. Quaranta S,
    5. Motta M,
    6. Segoloni G,
    7. Amoroso A
    : Membranous glomerulonephritis (MGN) in transplanted kidneys: Morphologic investigation on 256 renal allografts. Mod Pathol 6: 249–258, 1993
    OpenUrlCrossRefPubMed
  89. ↵
    1. Josephson MA,
    2. Spargo B,
    3. Hollandsworth DO,
    4. Thistlewait MD
    : The recurrence of membranous glomerulopathy in a renal transplant recipient: Case report and literature review. Am J Kidney Dis 24: 873–878, 1994
    OpenUrlPubMed
  90. ↵
    1. Innes A,
    2. Woodrow G,
    3. Boyd SM,
    4. Beckingham IJ,
    5. Morgan AG
    : Recurrent membranous nephropathy in successive renal transplants. Nephrol Dial Transplant 9: 323–325, 1994
    OpenUrlFREE Full Text
  91. ↵
    1. Heidet L,
    2. Gagnadoux ME,
    3. Beziau A,
    4. Niaudet P,
    5. Broyer M,
    6. Habib R
    : Recurrence of de novo membranous glomerulonephritis on renal grafts. Clin Nephrol 41: 314–318, 1994
    OpenUrlPubMed
  92. ↵
    1. Couchoud C,
    2. Pouteil-Noble C,
    3. Colon S,
    4. Touraine JL
    : Recurrence of membranous nephropathy after renal transplantation. Transplantation 59: 1275–1279, 1995
    OpenUrlPubMed
  93. ↵
    1. Odorico JS,
    2. Knechtle SJ,
    3. Rayhill SC,
    4. Pirsch JD,
    5. D'Alessandro AM,
    6. Belzer FO,
    7. Sollinger HW
    : The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 61: 228–234, 1996
    OpenUrlCrossRefPubMed
  94. ↵
    1. Marcen R,
    2. Mampaso F,
    3. Teruel JL,
    4. Rivera ME,
    5. Orofino L,
    6. Navarro-Antolin J,
    7. Ortuño J
    : Membranous nephropathy: Recurrence after kidney transplantation. Nephrol Dial Transplant 11: 1129–1133, 1996
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Cosyns JP,
    2. Couchoud C,
    3. Pouteil-Noble C,
    4. Squifflet JP,
    5. Pirson Y
    : Recurrence of membranous nephropathy after renal transplantation: Probability, outcome and risk factors. Clin Nephrol 50: 144–153, 1998
    OpenUrlPubMed
  96. ↵
    1. Lazowski P,
    2. Sablay LB,
    3. Glicklich D
    : Recurrent crescentic membranous nephropathy in two successive renal transplants: Association with choroidal effusions and retinal detachment. Am J Nephrol 18: 146–150, 1998
    OpenUrlCrossRefPubMed
  97. ↵
    1. Poduval RD,
    2. Josephson MA,
    3. Javaid B
    : Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol 23: 392–399, 2003
    OpenUrlCrossRefPubMed
  98. ↵
    1. Chan KW,
    2. Chan GS,
    3. Tang S
    : Glomerular pathology of allograft kidneys in Hong Kong. Transplant Proc 37: 4293–4296, 2005
    OpenUrlCrossRefPubMed
  99. ↵
    1. Carneiro-Roza F,
    2. Medina-Pestana JO,
    3. Moscoso-Solorzano G,
    4. Franco M,
    5. Ozaki K,
    6. Mastroianni-Kirsztajn G
    : Initial response to immunosuppressive and renoprotective treatment in posttransplant glomerulonephritis. Transplant Proc 38: 3491–3497, 2006
    OpenUrlCrossRefPubMed
  100. ↵
    1. Gallon L,
    2. Chhabra D
    : Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 6: 3017–3021, 2006
    OpenUrlCrossRefPubMed
  101. ↵
    1. Dabade TS,
    2. Grande JP,
    3. Norby SM,
    4. Fervenza FC,
    5. Cosio FG
    : Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study. Am J Transplant 8: 1318–1322, 2008
    OpenUrlCrossRefPubMed
  102. ↵
    1. Liebl R,
    2. Krämer BK
    : Recurrence and spontaneous remission of membranous nephropathy after renal transplantation. Clin Nephrol 70: 419–421, 2008
    OpenUrlPubMed
  103. ↵
    1. Weclawiak H,
    2. Ribes D,
    3. Guilbeau-Frugier C,
    4. Touchard G,
    5. Kamar N,
    6. Mehrenberger M,
    7. Modesto A,
    8. Rostaing L
    : Relapse of membranous glomerulopathy after kidney transplantation: Sustained remittance induced by rituximab. Clin Nephrol 69: 373–376, 2008
    OpenUrlPubMed
  104. ↵
    1. Sirimongkolrat T,
    2. Premasathian N,
    3. Vongwiwatana A,
    4. Limsrichamrern S,
    5. Cheunsuchon B,
    6. Vasuvattakul S
    : Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: A case report. Transplant Proc 40: 2440–2441, 2008
    OpenUrlCrossRefPubMed
  105. ↵
    1. El Kossi M,
    2. Harmer A,
    3. Goodwin J,
    4. Wagner B,
    5. Shortland J,
    6. Angel C,
    7. McKane W
    : De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant 22: 124–127, 2008
    OpenUrlPubMed
  106. ↵
    1. Aline-Fardin A,
    2. Rifle G,
    3. Martin L,
    4. Justrabo E,
    5. Bour JB,
    6. D'Athis P,
    7. Tanter Y,
    8. Mousson C
    : Recurrent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc 41: 669–671, 2009
    OpenUrlCrossRefPubMed
  107. ↵
    1. El-Zoghby ZM,
    2. Grande JP,
    3. Fraile MG,
    4. Norby SM,
    5. Fervenza FC,
    6. Cosio FG
    : Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 9: 2800–2807, 2009
    OpenUrlCrossRefPubMed
  108. ↵
    1. Sprangers B,
    2. Lefkowitz GI,
    3. Cohen SD,
    4. Stokes MB,
    5. Valeri A,
    6. Appel GB,
    7. Kunis CL
    : Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 5: 790–797, 2010
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Debiec H,
    2. Guigonis V,
    3. Mougenot B,
    4. Decobert F,
    5. Haymann JP,
    6. Bensman A,
    7. Deschênes G,
    8. Ronco PM
    : Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346: 2053–2060, 2002
    OpenUrlCrossRefPubMed
  110. ↵
    1. Beck LH Jr.,
    2. Bonegio RG,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
    OpenUrlCrossRefPubMed
  111. ↵
    1. Prunotto M,
    2. Carnevali ML,
    3. Candiano G,
    4. Murtas C,
    5. Bruschi M,
    6. Corradini E,
    7. Trivelli A,
    8. Magnasco A,
    9. Petretto A,
    10. Santucci L,
    11. Mattei S,
    12. Gatti R,
    13. Scolari F,
    14. Kador P,
    15. Allegri L,
    16. Ghiggeri GM
    : Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2. J Am Soc Nephrol 21: 507–519, 2010
    OpenUrlAbstract/FREE Full Text
  112. ↵
    1. Stahl R,
    2. Hoxha E,
    3. Fechner K
    : PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 363: 496–498, 2010
    OpenUrlCrossRefPubMed
  113. ↵
    1. Remuzzi G,
    2. Chiurchiu C,
    3. Abbate M,
    4. Brusegan V,
    5. Bontempelli M,
    6. Ruggenenti P
    : Rituximab for idiopathic membranous nephropathy. Lancet 360: 923–924, 2002
    OpenUrlCrossRefPubMed
  114. ↵
    1. Fervenza FC,
    2. Cosio FG,
    3. Erickson SB,
    4. Specks U,
    5. Herzenberg AM,
    6. Dillon JJ,
    7. Leung N,
    8. Cohen IM,
    9. Wochos DN,
    10. Bergstralh E,
    11. Hladunewich M,
    12. Cattran DC
    : Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117–125, 2008
    OpenUrlCrossRefPubMed
  115. ↵
    1. Molony DA,
    2. Craid JC
    1. Glassock RJ
    : Membranoproliferative glomerulonephritis. In: Evidence-Based Nephrology, edited by Molony DA, Craid JC. London, Wiley-Blackwell, 2009:183–196
  116. ↵
    1. Lorenz EC,
    2. Sethi S,
    3. Leung N,
    4. Dispenzieri A,
    5. Fervenza F,
    6. Cosio FG
    : Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 77: 721–728, 2010
    OpenUrlCrossRefPubMed
  117. ↵
    1. Braun MC,
    2. Stablein DM,
    3. Hamiwka LA,
    4. Bell L,
    5. Bartosh SM,
    6. Strife CF
    : Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study Experience. J Am Soc Nephrol 16: 2225–2233, 2005
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Little MA,
    2. Dupont P,
    3. Campbell E,
    4. Dorman A,
    5. Walshe JJ
    : Severity of primary MPGN, rather than MPGN type determines renal survival and post-transplant recurrence risk. Kidney Int 69: 504–511, 2006
    OpenUrlCrossRefPubMed
  119. ↵
    1. Morales JM
    : Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 36: 760–762, 2004
    OpenUrlCrossRefPubMed
  120. ↵
    1. Lien YH,
    2. Scott K
    : Long term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 35: 539–543, 2000
    OpenUrlCrossRefPubMed
  121. ↵
    1. Wu J,
    2. Jaar BG,
    3. Briggs WA,
    4. Choi MJ,
    5. Kraus ES,
    6. Racusen LC,
    7. Atta MG,
    8. Samaniego MD
    : High-dose mycophenolate mofetil in the treatment of post-transplant glomerular disease in the allograft: A case series. Nephron Clin Pract 98: c61–66, 2004
    OpenUrlCrossRefPubMed
  122. ↵
    1. Pickering MC,
    2. Cook HT
    : Translational mini-review series on complement factor H: Renal diseases associated with complement factor H: Novel insights form humans and animal. Clin Exp Immunol 151: 210–230, 2008
    OpenUrlCrossRefPubMed
  123. ↵
    1. Smith RJ,
    2. Alexander J,
    3. Barlow PN,
    4. Botto M,
    5. Cassavant TL,
    6. Cook HT,
    7. de Córdoba SR,
    8. Hageman GS,
    9. Jokiranta TS,
    10. Kimberling WJ,
    11. Lambris JD,
    12. Lanning LD,
    13. Levidiotis V,
    14. Licht C,
    15. Lutz HU,
    16. Meri S,
    17. Pickering MC,
    18. Quigg RJ,
    19. Rops AL,
    20. Salant DJ,
    21. Sethi S,
    22. Thurman JM,
    23. Tully HF,
    24. Tully SP,
    25. van der Vlag J,
    26. Walker PD,
    27. Würzner R,
    28. Zipfel PF
    ; Dense Deposit Disease Focus Group: New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18: 2447–2456, 2007
    OpenUrlAbstract/FREE Full Text
  124. ↵
    1. Andresdottir MB
    : Recommendations for the diagnosis and treatment of dense deposit disease. Nat Clin Pract Nephrol 4: 68–69, 2008
    OpenUrlPubMed
  125. ↵
    1. Licht C,
    2. Weyersberg A,
    3. Heinen S,
    4. Stapenhorst L,
    5. Devenge J,
    6. Beck B,
    7. Waldherr R,
    8. Kirschfink M,
    9. Zipfel PF,
    10. Hoppe B
    : Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor domain 15. Am J Kidney Dis 45: 415–421, 2005
    OpenUrlCrossRefPubMed
  126. ↵
    1. Saland JM,
    2. Ruggenenti P,
    3. Remuzzi G
    the Consensus Study Group: Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20: 940–949, 2009
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Ponticelli C,
    2. Villa M,
    3. Cesana B,
    4. Montagnino G,
    5. Tarantino A
    : Risk factors for late kidney allograft failure. Kidney Int 62: 1848–1854, 2002
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 5, Issue 12
1 Dec 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Posttransplant Recurrence of Primary Glomerulonephritis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
Citation Tools
Posttransplant Recurrence of Primary Glomerulonephritis
Claudio Ponticelli, Richard J. Glassock
CJASN Dec 2010, 5 (12) 2363-2372; DOI: 10.2215/CJN.06720810

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Posttransplant Recurrence of Primary Glomerulonephritis
Claudio Ponticelli, Richard J. Glassock
CJASN Dec 2010, 5 (12) 2363-2372; DOI: 10.2215/CJN.06720810
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • IgAN
    • FSGS
    • IMN
    • MPGN Types I and II (Dense Deposit Disease)
    • DDD
    • Conclusions
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • PDF

More in this TOC Section

  • Assessing Physical Function and Physical Activity in Patients with CKD
  • Effect of Red Cell Transfusions on Future Kidney Transplantation
  • Searching for Uremic Toxins
Show more In-Depth Reviews

Cited By...

  • Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation
  • Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis
  • Role of Anti-Phospholipase A(2) Receptor Antibodies in the Differential Diagnosis of Diabetic and Membranous Nephropathy
  • Transglutaminase is essential for IgA nephropathy development acting through IgA receptors
  • Recurrence of Secondary Glomerular Disease after Renal Transplantation
  • Scopus (147)
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

About

  • ASN
  • CJASN
  • ASN Journals
  • ASN Podcasts
  • CJASN Relaunch

Author Information

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • Reuse/Reprint Policy

More information

  • Advertise
  • Subscribe
  • Email Alerts
  • Sections by Topic
  • Password/Email Address Changes

© 2019 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire